ALASKA MEDICAID
Prior Authorization Criteria

Reyvow™ (lasmiditan)

FDA INDICATIONS AND USAGE[1]

Reyvow™ is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults and is not indicated for the preventive treatment of migraine.

APPROVAL CRITERIA[1,2,3]

1. Patient is 18 years of age or older **AND;**
2. Patient has a diagnosis of migraine headaches with or without aura **AND**;
3. Is being prescribed by or in consultation with a neurologist, pain specialist, or headache specialist **AND**;
4. The provider has ruled out medication overuse as a cause of migraines **AND**;
5. The patient has trialed at least 1 prophylactic medication (i.e. beta blocker, antiepileptic, antidepressant, etc.) for at least 2 months **AND;**
6. Patient has trialed 2 different triptans or has a contraindication (i.e. cardiovascular) to their use **AND;**
7. Patient agrees to not to drive or operate machinery until at least 8 hours after taking a dose.

DENIAL CRITERIA

1. Failure to meet approval criteria.

CAUTIONS[1,2,3]

- Patients should not take more than one dose in 24 hours.
- Reyvow™ can cause CNS depression, caution is advised when in combination with alcohol or other CNS depressants.
- Serotonin Syndrome has been observed and patients should discontinue if symptoms occur.
- Reyvow™ is not recommended in patients with severe hepatic impairment.
- Based on animal data, may cause fetal harm.

DURATION OF APPROVAL

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

QUANTITY LIMIT

- 50mg tablets - 8 per 30 days
- 100mg tablets - 8 per 30 days

REFERENCES / FOOTNOTES:

1. Reyvow™ (lasmiditan) [package insert]. Indianapolis, IN. Lilly USA, LLC; October 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf Accessed September 30, 2020
2. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894-1904.
3. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18.